Wikisage, the free encyclopedia of the second generation, is digital heritage

Difference between revisions of "Belzutifan"

From Wikisage
Jump to navigation Jump to search
(Created page with "Belzutifan is a drug being approved for the treatment of renal cell carcinoma associated with von Hippel-Lindau disease. Belzutifan is an inhibitor of hypoxia-inducible facto...")
 
 
(11 intermediate revisions by the same user not shown)
Line 1: Line 1:
Belzutifan is a drug being approved for the treatment of renal cell carcinoma associated with von Hippel-Lindau disease.
+
Belzutifan is a drug being approved for the treatment of renal cell carcinoma associated with von [[Hippel-Lindau disease]].
  
 
Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α).
 
Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α).
Line 5: Line 5:
 
Belzutifan is the first drug to be awarded an "innovation passport" by the UK Medicines and Healthcare products Regulatory Agency (MHRA)<ref>https://en.wikipedia.org/wiki/Medicines_and_Healthcare_products_Regulatory_Agency</ref>
 
Belzutifan is the first drug to be awarded an "innovation passport" by the UK Medicines and Healthcare products Regulatory Agency (MHRA)<ref>https://en.wikipedia.org/wiki/Medicines_and_Healthcare_products_Regulatory_Agency</ref>
  
==ATC==
+
==[[ATC]]==
<gallery>File:Belzutifan.png</gallery>
+
 
 +
none
 +
{| style="background:Ivory; color:black" border=1 cellspacing=1 cellpadding=5
 +
|colspan=2| <center>[[File:Belzutifan.png|92px]]
 +
: [[wikipedia:belzutifan|belzutifan]] </center>
 +
|}
 +
[[File:Buecher_Regal_636.jpg|32px]]
 +
Retinal angioma associated with cerebellar angioma and sometimes angioma in other organs<ref>Dictionary of Medical eponyms</ref>
 +
 
 +
==External links==
 +
[https://www.karger.com/Article/FullText/431323 Ben-Skowronek I, Kozaczuk S] 2015: Von Hippel-Lindau Syndrome. Horm Res Paediatr 84:145-152. doi: 10.1159/000431323
 +
 
 +
{{wikidata|Q27456641}}
 +
 
 +
 
 +
{{refs}}
 +
 
 +
[[nl:Belzutifan]]

Latest revision as of 00:05, 14 August 2021

Belzutifan is a drug being approved for the treatment of renal cell carcinoma associated with von Hippel-Lindau disease.

Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α).

Belzutifan is the first drug to be awarded an "innovation passport" by the UK Medicines and Healthcare products Regulatory Agency (MHRA)[1]

ATC

none

Belzutifan.png
belzutifan

Buecher Regal 636.jpg Retinal angioma associated with cerebellar angioma and sometimes angioma in other organs[2]

External links

Ben-Skowronek I, Kozaczuk S 2015: Von Hippel-Lindau Syndrome. Horm Res Paediatr 84:145-152. doi: 10.1159/000431323

Q27456641 op Wikidata  Interwiki via Wikidata


References

References: